State of the art: gastrointestinal malignancies in the human immunodeficiency virus (HIV) population.
The gastrointestinal tract is one of the most common sites for the development of primary neoplasms arising in patients with pre-existing infection with the human immunodeficiency virus (HIV). Over the past decade, new information on the clinical manifestation, natural history, treatment options, and related toxicity have been reported, mostly notably the integration of highly active antiretroviral therapy (HAART). The following is a concise review summarizing the current state-of-the-art for GI tract malignancies in the HIV-positive patient and is designed to assist the clinical oncology team in developing a rationale plan when caring for these patients.
Koshy
Mary
M
Department of Radiation Oncology, Department of Radiation Oncology, Emory University School of Medicine, 1365 Clifton Rd NE, Atlanta, GA 30344, USA.
Kauh
John
J
Gunthel
Clifford
C
Joyner
Melissa
M
Landry
Jerome
J
Thomas
Charles R
CR
D023241:Antiretroviral Therapy, Highly Active; D001005:Anus Neoplasms / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D005770:Gastrointestinal Neoplasms / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008223:Lymphoma / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D011379:Prognosis; D012307:Risk Factors; D012514:Sarcoma, Kaposi / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy